Thrombin receptor activation peptide induces pulmonary vasoconstriction

Area of Science:

• Cardiovascular Physiology
• Pulmonary Circulation Research
• Smooth Muscle Pharmacology

Background:

• Alpha-thrombin activates protease-activated receptor-1 (PAR-1) on smooth muscle cells.
• Thrombin receptor activating peptides (TRAP) mimic alpha-thrombin's effects.
• Pulmonary vasoconstriction and hypertension are critical cardiovascular events.

Purpose of the Study:

• To investigate the role of TRAP-14 in alpha-thrombin-induced pulmonary vasoconstriction.
• To compare the effects of TRAP-14 and alpha-thrombin on pulmonary hemodynamics.
• To examine the impact of these agonists on smooth muscle cell calcium and desensitization.

Main Methods:

• Isolated guinea pig lungs perfused with Ringer-albumin solution.
• Dose-dependent administration of TRAP-14 and alpha-thrombin.
• Measurement of pulmonary arterial and venous pressures.
• Stimulation of cultured pulmonary artery smooth muscle cells to assess cytosolic Ca2+.
• Desensitization studies in both cell cultures and perfused lungs.

Main Results:

• TRAP-14 and alpha-thrombin induced dose-dependent pulmonary vasoconstriction and hypertension.
• Both agonists primarily caused venoconstriction, leading to hypertension.
• TRAP-14 and alpha-thrombin increased cytosolic Ca2+ in smooth muscle cells, followed by desensitization.
• Desensitization to alpha-thrombin was longer-lasting than to TRAP-14 in perfused lungs.

Conclusions:

• TRAP-14 effectively mimics alpha-thrombin-induced pulmonary vasoconstriction and hypertension.
• Pulmonary venoconstriction is a key mechanism for both agonists.
• Differential desensitization patterns suggest distinct receptor interactions or downstream signaling pathways.